Accelerating Access to Optimal Child-Friendly Antiretroviral Formulations
Overview
Transitioning children to new ARV formulations or regimens requires careful assessment and planning, accurate quantification and supply planning of the full range of WHO-recommended pediatric ARVs, updated national policies and guidelines, capacity building of health care providers and caregivers, and demonstrations and close follow-up thereafter to sustain quality of care. Standardized training, mentorship, monitoring, and evaluation tools need to be developed, harmonized, and used by all key stakeholders and implementers to avoid silos.
Read more lessons learned in accelerating access to optimal child-friendly ARV formulas from Tanzania in our technical report.
Tanzania
HIV Treatment Optimization; Pediatric HIV Diagnosis, Care & Treatment